Ausztrália - angol - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated newcastle disease virus antigen - misc. vaccines or anti sera - inactivated newcastle disease virus antigen vaccine-viral active 0.0 p - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - newcastle disease | vaccine | equine rotavirus

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 10mg;  ;  ;  ;   - film coated tablet - 10 mg - active: simvastatin 10mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 20mg;  ;  ;  ;   - film coated tablet - 20 mg - active: simvastatin 20mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 40mg;  ;  ;  ;   - film coated tablet - 40 mg - active: simvastatin 40mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 80mg;  ;  ;  ;   - film coated tablet - 80 mg - active: simvastatin 80mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - miconazole 20 mg/g;   - oral gel - 2% w/w - active: miconazole 20 mg/g   excipient: ethanol cocoa glycerol orange flavour polysorbate 20 potato starch purified water saccharin sodium - daktarin oral gel is indicated for the treatment of clinically significant oral and gastrointestinal candidiasis.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - salcatonin 100 iu/ml;  ;   - solution for injection - 100 iu/ml - active: salcatonin 100 iu/ml     excipient: glacial acetic acid nitrogen sodium acetate trihydrate sodium chloride water for injection - acute bone pain associated with hip arthroplasty osteolysis and osteoporotic vertebral compression fracture.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - domperidone 10mg;   - tablet - 10 mg - active: domperidone 10mg   excipient: cottonseed oil, hydrogenated hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone purified water   sodium laurilsulfate   starch - adults and adolescents weighing 35kg or more: symptomatic treatment of the dyspeptic symptom complex that may be associated with delayed gastic emptying such as epigastric sense of fullness, abdominal distension or swelling, or epigastric pain or discomfort.

Új-Zéland - angol - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - levamisole hydrochloride - levamisole hydrochloride 40 g/litre - endoparasiticide

Új-Zéland - angol - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - copper (ii) oxide - copper (ii) oxide 1,000 g/kg - oral nutrient/electrolyte